Sanofi announced that Belén Garijo will take the helm as chief executive officer, effective May 1, 2026. Garijo, a former senior executive at Merck KGaA, brings a decade of oncology and immunology expertise and previously led the integration of Genzyme into Sanofi’s corporate structure.
The company’s Q1 2026 results, released the same day, surpassed expectations with revenue of $12.14 billion versus a forecast of $10.25 billion, and earnings per share of $2.17 versus $1.79. The revenue beat was driven by a 31 % jump in Dupixent sales to nearly $4.9 billion and a 49.6 % increase in pharma launch sales to €1.2 billion. Operating expenses rose 7 % in absolute terms, but as a percentage of sales they fell 1.9 percentage points, reflecting improved operational efficiency and a favorable product mix.
Paul Hudson’s departure earlier in the year followed a series of pipeline setbacks, most notably the failure of the tolebrutinib trial. The board’s decision to appoint Garijo was framed as a move to strengthen execution discipline, refine capital allocation, and translate scientific advances into sustainable performance.
Garijo’s mandate, as outlined by the board, focuses on tightening execution discipline, sharpening capital allocation, and ensuring that the company’s scientific strengths translate into consistent financial results. Interim CEO Olivier Charmeil highlighted the company’s strong start to 2026, noting “double‑digit sales and business EPS growth” as evidence of the strategy’s effectiveness.
Investors responded positively to the earnings beat and the reaffirmation of 2026 guidance, which projects high‑single‑digit sales growth at constant exchange rates and business EPS growth slightly faster than sales. The strong Q1 performance, particularly the robust Dupixent sales and successful integration of recent acquisitions, underpins confidence in Sanofi’s biopharma focus and its broader transformation strategy.
The appointment of Garijo, coupled with the company’s solid Q1 results, signals a renewed emphasis on operational efficiency and capital discipline, positioning Sanofi to capitalize on its immunology portfolio while navigating the challenges of a competitive biopharma landscape.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.